Olympus Corp.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: JP3201200007
JPY
1,662.50
16.5 (1.0%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

3.44 M

Shareholding (Mar 2026)

FII

0.00%

Held by 1 FIIs

DII

100.00%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

High Management Efficiency with a high ROE of 17.09%

 
2

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 1.07 times

 
3

Flat results in Mar 26

4

With ROE of 11.32%, it has a fair valuation with a 2.02 Price to Book Value

5

Majority shareholders : Non Institution

 
6

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

JPY 2,054,554 Million (Large Cap)

stock-summary
P/E

18.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.05

stock-summary
Return on Equity

11.32%

stock-summary
Price to Book

2.66

Revenue and Profits:
Net Sales:
295,281 Million
(Quarterly Results - Mar 2026)
Net Profit:
24,815 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
21.0%
0%
21.0%
6 Months
-16.6%
0%
-16.6%
1 Year
-11.24%
0%
-11.24%
2 Years
-33.98%
0%
-33.98%
3 Years
-29.15%
0%
-29.15%
4 Years
-38.29%
0%
-38.29%
5 Years
-27.69%
0%
-27.69%

Olympus Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
6.47%
EBIT Growth (5y)
13.43%
EBIT to Interest (avg)
21.20
Debt to EBITDA (avg)
0.43
Net Debt to Equity (avg)
-0.01
Sales to Capital Employed (avg)
0.94
Tax Ratio
26.02%
Dividend Payout Ratio
19.42%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
22.60%
ROE (avg)
17.09%

Valuation key factors

Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
2.02
EV to EBIT
10.43
EV to EBITDA
7.23
EV to Capital Employed
1.97
EV to Sales
1.62
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
18.87%
ROE (Latest)
11.32%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 8.51% vs 5.61% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -40.12% vs 47.13% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "295,281.00",
          "val2": "272,111.00",
          "chgp": "8.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "69,965.00",
          "val2": "77,321.00",
          "chgp": "-9.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "516.00",
          "val2": "544.00",
          "chgp": "-5.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-23,885.00",
          "val2": "-3,569.00",
          "chgp": "-569.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "24,815.00",
          "val2": "41,443.00",
          "chgp": "-40.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "180.90%",
          "val2": "220.80%",
          "chgp": "-3.99%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 1.34% vs 7.73% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is -42.13% vs 235.95% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,010,676.00",
          "val2": "997,332.00",
          "chgp": "1.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "214,226.00",
          "val2": "252,494.00",
          "chgp": "-15.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "9,284.00",
          "val2": "4,821.00",
          "chgp": "92.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-41,808.00",
          "val2": "-23,539.00",
          "chgp": "-77.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "68,172.00",
          "val2": "117,800.00",
          "chgp": "-42.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "145.50%",
          "val2": "186.50%",
          "chgp": "-4.10%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoYstock-summary

Mar'26
Mar'25
Change(%)
Net Sales
295,281.00
272,111.00
8.51%
Operating Profit (PBDIT) excl Other Income
69,965.00
77,321.00
-9.51%
Interest
516.00
544.00
-5.15%
Exceptional Items
-23,885.00
-3,569.00
-569.24%
Consolidate Net Profit
24,815.00
41,443.00
-40.12%
Operating Profit Margin (Excl OI)
180.90%
220.80%
-3.99%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2026 is 8.51% vs 5.61% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -40.12% vs 47.13% in Mar 2025

Annual Results Snapshot (Consolidated) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1,010,676.00
997,332.00
1.34%
Operating Profit (PBDIT) excl Other Income
214,226.00
252,494.00
-15.16%
Interest
9,284.00
4,821.00
92.57%
Exceptional Items
-41,808.00
-23,539.00
-77.61%
Consolidate Net Profit
68,172.00
117,800.00
-42.13%
Operating Profit Margin (Excl OI)
145.50%
186.50%
-4.10%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 1.34% vs 7.73% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is -42.13% vs 235.95% in Mar 2025

stock-summaryCompany CV
About Olympus Corp. stock-summary
stock-summary
Olympus Corp.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available